Pharma Firms See Opportunity in Increased Scrutiny by U.S.

Indian pharmaceutical firms are unfazed by the prospect of increased scrutiny by U.S. regulator Food and Drug Administration (FDA), which faces charges of slipping up on inspection of non-U.S. drugmakers.
Livemint.com